Jay Cho, Ph.D. is a Partner in the firm’s Litigation department with a focus on patent litigation, particularly in the pharmaceutical and biotechnology space. Throughout his career, Jay has been involved in numerous patent cases related to, among other technologies, small molecules, polypeptides, vaccines, and antibodies in U.S. District Courts and before the Patent Trial and Appeal Board.

Jay has litigated numerous patent cases brought under the Hatch-Waxman Act, and as a trial attorney, Jay had a major role in contributing to the recent victory for the innovator involving a blockbuster antipsychotic drug. With a deep knowledge in biochemistry, molecular biology and genetics, Jay has also represented pharmaceutical companies in various matters involving antibodies and antibody-related products.

Jay is a member of the New York Intellectual Property Law Association.

Select Patent Matters

  • Representing a major pharmaceutical company in a Hatch-Waxman patent litigation involving patents for administering an intranasal antidepressant drug.
  • Representing a major pharmaceutical company and obtained multiple trial victories in Hatch-Waxman patent litigations involving a dosing regimen patent for administering a long-acting injectable antipsychotic drug.
  • Representing a major pharmaceutical company and obtained a trial victory in a Hatch-Waxman patent litigation involving a missed dose regimen patent for a long-acting injectable antipsychotic drug.
  • Representing a footwear company in district court patent litigations involving multiple patents.
  • Counseled a major pharmaceutical company on matters involving chimeric antigen receptor T-cell therapy (CAR-T) technology.
  • Counseled a pharmaceutical company on matters involving CRISPR technology.
  • Counseled a pharmaceutical company on matters involving producing antibody drugs.
  • Represented a fitness company in district court and at the USPTO involving patents for indoor cycling.
  • Represented a major pharmaceutical company in patent disputes involving multiple antibody drugs.

Pro Bono Matters

  • Represented multiple families in special education due process hearings.

  • U.S. Patent and Trademark Office
  • New York

  • Korean

  • Fordham University School of Law (J.D., 2014)
  • Johns Hopkins University School of Medicine (Ph.D., 2012)
    • Biochemistry, Cellular and Molecular Biology, and Neuroscience
  • Korea University (B.S., 2005)
    • Life Sciences

  • Panelist, "Navigating Parallel Proceedings: Strategies for Maneuvering Through BPCIA, PTAB and District Courts," The American Conference Institute's 16th Summit on Biosimilars & Innovator Biologics (June 3, 2025)